Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ATXS 
Astria Therapeutics Inc (ATXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ATXS (3-star) is a STRONG-BUY. BUY since 20 days. Simulated Profits (49.35%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $24.6
1 Year Target Price $24.6
| 7 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 253.79% | Avg. Invested days 57 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 701.49M USD | Price to earnings Ratio - | 1Y Target Price 24.6 |
Price to earnings Ratio - | 1Y Target Price 24.6 | ||
Volume (30-day avg) 9 | Beta 0.07 | 52 Weeks Range 3.56 - 12.71 | Updated Date 11/7/2025 |
52 Weeks Range 3.56 - 12.71 | Updated Date 11/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.02 |
Earnings Date
Report Date 2025-11-12 | When - | Estimate -0.4188 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.28% | Return on Equity (TTM) -38.49% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 274896334 | Price to Sales(TTM) - |
Enterprise Value 274896334 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.57 | Shares Outstanding 56434894 | Shares Floating 37732934 |
Shares Outstanding 56434894 | Shares Floating 37732934 | ||
Percent Insiders 0.49 | Percent Institutions 97.28 |
Upturn AI SWOT
Astria Therapeutics Inc
Company Overview
History and Background
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for rare and life-threatening allergic and immunological diseases. Founded in 2019, it is relatively young, with its primary focus on hereditary angioedema (HAE).
Core Business Areas
- Hereditary Angioedema (HAE) Program: Focuses on developing STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, for the treatment of HAE attacks.
Leadership and Structure
The company is led by a management team with expertise in drug development and rare diseases. Details on specific individuals and the full organizational structure can be found on their investor relations website.
Top Products and Market Share
Key Offerings
- STAR-0215: A monoclonal antibody inhibitor of plasma kallikrein being developed for the treatment of HAE attacks. It is currently in clinical trials. Market share data is not applicable, as it is still in development. Competitors include Takeda (TAK) with Takhzyro and CSL Behring (CSL) with Berinert, and BioCryst Pharmaceuticals (BCRX) with Orladeyo.
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on rare diseases is characterized by high unmet needs and significant market opportunities. There is a strong demand for effective and safe therapies for HAE.
Positioning
Astria Therapeutics is positioned as an innovator in the HAE space with its novel monoclonal antibody approach. Its competitive advantage relies on the potential for improved efficacy, dosing convenience, or safety compared to existing treatments.
Total Addressable Market (TAM)
The global hereditary angioedema (HAE) market is estimated to be several billion USD. Astria Therapeutics aims to capture a significant portion of this market with STAR-0215, pending successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach (STAR-0215)
- Strong focus on HAE
- Experienced management team
- Potential for differentiated product profile
Weaknesses
- Early stage clinical development (high risk)
- Reliance on a single product candidate
- Limited commercial infrastructure
- Subject to regulatory approval risks
Opportunities
- Positive clinical trial results
- Partnerships and collaborations
- Expansion into other rare disease indications
- Acquisition by a larger pharmaceutical company
Threats
- Competition from established HAE therapies
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- TAK
- CSL
- BCRX
Competitive Landscape
Astria Therapeutics is a late comer to the HAE treatment, and the market is currently led by Takeda(TAK) and CSL (CSL). BCRX is also a competitor with an oral medicine. ASTX has no market share but the potential to win some of that market share if their clinical trials are successful and they obtain regulatory approval and market launch.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage. Future growth depends on the success of STAR-0215.
Future Projections: Future growth is tied to successful clinical trials of STAR-0215, regulatory approvals, and eventual market launch and adoption. Analyst estimates vary.
Recent Initiatives: Recent initiatives are focused on advancing STAR-0215 through clinical development, including enrolling patients in clinical trials and presenting data at scientific conferences.
Summary
Astria Therapeutics is a pre-revenue biopharmaceutical company developing STAR-0215 for HAE. Its success hinges on positive clinical trial results and regulatory approval. The company faces competition from established HAE therapies. They need to successfully compete against established companies. The company has enough funding to complete its initial clinical trials and the risk to the company is regulatory approval.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Astria Therapeutics Investor Relations
- SEC Filings (10-K, 10-Q)
- Company Presentations
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Market share data is estimated and may vary. Clinical trial outcomes are uncertain.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Astria Therapeutics Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2015-06-25 | Co-Founder, CEO, President & Director Ms. Jill C. Milne Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 78 | Website https://www.astriatx.com |
Full time employees 78 | Website https://www.astriatx.com | ||
Astria Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is navenibart, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in clinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.